Remove Government Remove Leads Remove Networking Remove Training
article thumbnail

Data integrity considerations in Pharma and Life Sciences

European Pharmaceutical Review

Life science companies are increasingly using advanced technologies like artificial intelligence (AI), machine learning (ML) and blockchain to improve data quality and integrity by detecting anomalies in data and establishing tamper-proof audit trails for all data-related activities Data governance. Training and education.

article thumbnail

Championing UK ATMP clinical trials

European Pharmaceutical Review

Specifically, an additional four years of funding for the Advanced Therapy Treatment Centre (ATTC) Network is available through the programme. The funding will start with three established Centres, and then across an expanded network, according to Chief Clinical Officer for Cell and Gene Therapy Catapult, Jacqueline Barry.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Future of Medical Sales Careers: Trends, Challenges, and Opportunities

Rep-Lite

Regulatory Changes and Compliance Challenges Navigating the intricacies of healthcare sales involves staying attuned to the ever-evolving regulatory framework that governs the industry. Finally, take a consultative approach, focusing on clients’ specific challenges and goals.

article thumbnail

Why Is FDA Issuing Fewer Marketing Violation Letters?

Pharma Marketing Network

While maintaining a vigilant approach to marketing compliance is crucial, the FDA may be strategically choosing to address more immediate public health concerns, leading to fewer marketing violation letters being issued. appeared first on Pharma Marketing Network. The post Why Is FDA Issuing Fewer Marketing Violation Letters?

article thumbnail

UK medicines manufacturing must remain domestic

European Pharmaceutical Review

With the right policies in place, the UK can be the best global location for innovative and environmentally sustainable innovative medicines manufacturing” Increasing Government investment, alongside other policy changes, could release a further £15 billion in company investment over the next decade, according to the MMIP.

article thumbnail

Guaranteeing resilience in vaccine manufacturing

European Pharmaceutical Review

A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre. There has been a steady stream of developments in the vaccine manufacturing space throughout 2023.

article thumbnail

The Ethical Challenges for Pharmaceutical Marketers in Using AI to Write Marketing Copy or Creative

Pharma Marketing Network

AI algorithms are only as unbiased as the data they are trained on, and if that data is biased, the algorithm will also be biased. For example, if an AI system is trained on data that is skewed towards certain demographic groups, it may create marketing campaigns that are discriminatory towards other groups (1). Crown, 2016. (3)

Ethics 52